A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) (BRAVE II)

I4V-MC-JAIA -

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Systemic Lupus Erythematosus
What the trial is testing?
Baricitinib
Could I receive a Placebo?
Yes
Enrollment Goal
778
Trial Dates
Aug 2, 2018 - Oct 20, 2021
How long will I be in the trial?
The study will last up to 62 weeks and may include up to 17 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have had systemic lupus erythematosus (SLE or lupus) for at least 6 months

  • Participants must have currently active manifestations of lupus

Participants Must Not:

  • Participants must not have severe lupus nephritis

  • Participants must not have severe central nervous system lupus

  • Participants must not have or Have had another serious medical condition

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.